Summary for reducing anti-PD-1 resistance by STING-LNP (IMAGE)
Caption
Summary for reducing anti-PD-1 resistance by STING-LNP. The STING-LNPs were intravenously injected into mice, delivering immune-signaling molecules to the liver. This stimulated the production of IFN-1 by liver macrophages, which in turn activated the NK cells in the lung and spleen. The effect of NK cells is limited by PD-L1; when STING-LNPs are combined with Anti-PD-1 therapy, the NK cells are able to act fully and destroy cancer cells. IFN, interferon; NK, natural killer; PD-1, programmed cell death 1; STING-LNP, lipid nanoparticle containing a stimulator of an interferon gene (Takashi Nakamura, et al. Journal for ImmunoTherapy of Cancer. July 2, 2021).
Credit
Takashi Nakamura, et al. Journal for ImmunoTherapy of Cancer. July 2, 2021
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC